, , ,

<<


 >>  ()
Pages:     | 1 |   ...   | 12 | 13 ||

- ...

-- [ 14 ] --

Streptococcus pyogenes , , ( , , - ). , , . , , .

14 (58,3%). 9 1 , 3 2, 2 3 . , 5 14 (35,7%). , , -- ( 2 , ). , , , , . , , ;

, , [8].

, , . 19 (79,2%) 156,3 312,5 / ( 247,3 11,7 /) 1 4 ( 1,6 0,2).

, , 10 19 (52,6%). , , ( 20%). 2 19 , ( , ). 17 (89,5%) .

:

1. . . . : - , . , . 58- . - ( ) (). - .

2. . ( ), 12 , ( ). 34 , ( ).

3. Streptococcus pyogenes . , , ( ).

4. Streptococcus pyogenes , ( , , - ). - ( ) , , . , , .

5. , , ;

, , .

6. (89,5%) : , ( ). ( 1- 2- ).

1. , .. , varizella-zoster : .-. / .. , .. . , 2009. 32 .

2. Feigin and Cherrys textbook of pediatric infectious diseases / R.D. Feigin [et al.]. 6th ed. Elsevier Health Sciences, 2009. Vol. 2. P. 20772088.

3. Gnann, J.W. Varicella-zoster virus: atypical presentations and unusual complications / J.W. Gnann // J. Infect. Dis. 2002. Vol. 186 (suppl. 1). S. 9198.

4. Nelson textbook of pediatrics / R.M. Kliegman [et al.]. 18th ed. Saunders, 2008. P. 13661372.

5. , .. / .. , .. ;

. .:

, 1990. . 128141.

6. Solomon, T. Viral encephalitis: a clinicians guide / T. Solomon, I.J. Hart, N.J. Beeching // Pract.

Neurol. 2007. Vol. 7. P. 288305.

7. / . .. , .. , .. . : , 2007. . 101112, 244245.

8. , .. ( ) : / .. , .. , .. // . . 2005. 11. . 1014.

9. Severe invasive group A streptococcal infections: a subject review / American Academy of Pediatrics. Committee on Infectious Diseases // Pediatrics. 1998. Vol. 101, 1. P. 136140.

11.07. ComplICaTIoNS of ThE ChICkENpoX IN ChIldREN poznyak T.v., Scheremet a.N., ocheretniy m.d., Buldyk E.a., Rusikevich S.S., komir v.v., valkovich E.m., volkova N.g., kepet v.a., klyuchareva a.a., kudin a.p.

Belarusian State Medical University;

Belarusian Medical Academy of Post-Graduate Education;

Municipal Children's Infection Clinical Hospital, Minsk, Belarus Purulent complications (PC) are the most often complications of a chickenpox in children. The leading part in PC development plays Streptococcus pyogenes. Starting antibacterial therapy should include a combina tion ceftriaxone with clindamicin. It is necessary to include purpose of an intravenous immunoglobulin in com plex treatment of such children as soon as possible. Absence of clinical and paraclinical effects from such therapy testifies to formation purulently-necrosis inflammations. It demands operative treatment, as a rule, without neces sity of replacement of antibacterial therapy. The CNS defeats on a background chickenpox develop seldom and in most cases proceed as cerebellar ataxia. Attributes of cerebellar ataxia appear after the termination of rasch, is usual on 5-8-th day from the beginning of chickenpox and are connected with immunopathological inflamma tion. In clinical characteristic of cerebellar ataxia the absence or weak expressiveness of the system inflammato ry response syndrome pays to itself. There is no necessity for antivirus therapy (acyclovir). Application of gluco corticosteroids is proved and it can be recommended for acceleration of recovery.

keywords: chickenpox, complications, children, antibacterial therapy, intravenous immunoglobu lin, cerebellar ataxia.

..

, , , , -4.

: , , , .

. , Th1 Th2, .. , . , , Th1 Th2, , .

, - , Th0 CD4+- Th1 Th2. -12, , Th0 CD4+- Th1. , -18 (Th1-). -12 -1, , -, , , . 1 -12, , .

.

Th1 Th2 . -12 Th2. -4 10 Th1. 4 10 , , - -, , B- . , -, . 2 Th2, -4 -10 , [1].

, -4 .

. A/FPV/ Rostock/34 (H7N1), : , Saponaria officinalis Gipsophila paniculata.

( ) . 0,2 .

(30 /), (0,5 /) (15 /).

2 .

1 2- .

, R&D systems. . . TECAN.

. ( , ) -4 ( ) , 10 .

, / -4 10%, 2- . . . -, -4 - I [2]. -, -4 -, . -, -, . -4 , . , II Fc- IgG, , [3].

. , , , -4, .

1. , .. [ ] / .. // . 2005. 3. : http://www.cytokines.ru/russian/2005/3/ Art23.php. : 25.07.2011.

2. , .. : / .. . ., 2000. 112 .

3. , .. / .. // . 2003. . 4, 3. . 131139.

29.07. STUdy of INflUENCE of ImmUNoSTImUlaNT STRUCTURE oN CEllUlaR ImmUNE RESpoNSE abitayeva m.S.

Institute of Microbiology and Virology, Almaty, Kazakhstan Immunopotentiators belonging to the different structural groups with different intensity could induce synthesis of IL-4.

keywords: cellular immunity, adjuvant, cytokine, enzyme immunoassay.

..

. .. , , . .

, -21, 7,5 lg 50/ 0,010,1 50, 8,0 lg 50/.

: , , , , .

. , , , . . [14].

. . 108109 50/ [5, 6].

. , [5, 6].

. . -21. 1,5- . . 1 . 150 3 . 37 0,5 . . 17- . 40 25 . - , 12 .

.

. 101 , 9,0 3 , 1,0 3 , . 1 9 , , 1 , 9 , , : 101, 102, 103, 104, 105, 106, 107, 108.

-21 ( ). -21 0,2 3 (101, 102, 103, 104, 105, 106, 107, 108) . , 37 0,5 , , 0,8 . (50/) .

BHK-21, PK-15, C MDBK. , .

. -21, , 15, . 0,1, 0,01 0, 50 . 12 4,27,5 lg 50/. 7 . 1.

1 , lg 50/ -21 + 6,07, -15 + 6, + 4,25, + 5, 1, -21 -15, 6,07,5 6,0 lg 50/ . -21, , ( 2 4 ).

. 0,001 0,1 50. 2448 . 2.

2 - , 50 , , lg 50/ 0,2 24 7, 0,1 24 7, 0,01 24 7, 0,001 48 6, 2, -21 0,01 0,1 50, 7,0 7,5 lg 50/ . 0,2 50 .

, -21 , . 7 3,5 lg 50/.

3, 7,258,0 lg 50/, 6,07,5 lg 50/. , 7 .

3 - , lg 50/ , lg 50/ 1 + 3,5 3, 2 + 4,0 4, 3 + 4,66 5, 4 + 5,3 6, 5 + 6,0 7, 6 + 7,5 8, 7 + 7,5 7, . , :

- -21 ;

- 7,5 lg 50/;

- 0,010,1 50;

- , , 8,0 lg 50/ .

1. ( ) [ ]. ., . . (2,33 ). ., 2007. 1 . . (CD-ROM).

2. , .. / .. // 100 : . .-.

. , 1996. . 4257.

3. , .. / .. , .. , .. // : . .-. . , 2003. . 2. . 562566.

4. , .. / .. , .. . : , 1990. 152 .

5. , .. ɻ / .. , .. // . . -. 2007. 5 . 5557.

6. / .. [ .] // : .-. . . , 1995. . 147148.

13.09. CUlTIvaTIoN opTImIZaTIoN of aUJESZky'S dISEaSE vIRUS pRodUCTIoN STRaIN Erokhovets N.f.

S.N. Vyshelessky Research Institute for Experimental Veterinary, Minsk, Belarus Article is devoted to selection of optimum parameters of cultivation of Aujeszky's disease virus for its maximum accumulation to vaccine industrial production. It is established that the most suitable cell cul ture for virus accumulation is -21, maximum virus title in stationary way cultivation is 7,5 lg CD50/ cm3 in plurality infection 0,010,1 CD50, and in "spinner-culture" method 8,0 lg CD50/cm3.

keywords: Aujeszky's disease virus, pigs, cultivation, optimization, production strain.

.. .. 147, .. 149 .. .. 77 .. .. 293 .. .. 114 .. .. 186 . .. 137 .. .. 122 .. .. 13 .. .. 13, 56, 60, 173 .. 38, .. 230 .. .. 44, 214 .. .. 193 .. .. .. 16, 21, 28, .. 56, .. 155 .. .. 56 .. .. 100 .. .. 177 .. .. .. 73 .. .. 177 .. .. 100 .. .. 177, 204 M. .. 183 .. 106, .. 177, .. .. .. 56, 60, .. .. .. .. .. .. 147, .. .. 44, 47, .. .. 134, 137, .. 77, .. .. .. .. .. 122, .. .. 102, 103, .. .. .. A.C. 152, 168, .. .. .. .. .. .. .. .. .. 3, 13, 152, .. .. .. .. .. 183 .. 183, 220, .. 77, 81 .. .. 56 .. .. .. 186, 199 .. 129, 186, .. 65 .. 16, .. 32, 142 .. .. 227, 262 .. .. 147 .. .. 287 .. .. 238 .. .. 199 .. 3, 114, 166, .. 287 .. 183, .. 234 .. . . 65, 86, 90 .. 56, .. .. .. .. .. .. .. .. .. .. .. 152, .. .. .. .. .. .. .. .. .. .. .. .. 32, .. .. .. 77, .. .. .. .. 90, 227, .. .. .. 102, 103, .. 44, 47, .. 44, 47, .. 68 .. 44, 47, .. 129 . .. 267 .. .. 129 .. 183, .. 220, 279 .. .. 44 .. .. 238 .. .. 106, 230 .. .. 16, .. .. .. 65 .. .. 258 .. .. 129 .. .. 51 .. 177, .. 199 .. .. 238 .. .. .. 152, .. 102, 103, B .. Boka V. .. .. C .. .. 3, 16, 21, 94, 244, 250, Chapenko S. 274, .. Cunskis E. .. .. 86, f . Folkmane I. .. g Gintere S. M. Gravelsina S. .. k Karelis G. .. Krmia A. .. .. l .. 152, Logina I. .. m Murovska M. 274, .. N Nora-Krukle Z. .. p .. 220, .. Pheby D. R .. 77, Rozental R. .. .. S .. .. Sprudzns G. .. Sultanova A. 274, .. .. 152, v . .. 16, 21, 28, Vksna L. .. Z .. 230 Ziedina I.

1. , , , .

2. 1- . Times New Roman 12 , ( ) 1 , , , 25 .

3. , , , 57 4, 12 .

4. .

5. :

1) ;

2) ;

3) , , .

6. ( ) . ( 10 ) , , . ( 5).

7. : , , , ;

: , , ;

(). ( ), .

8. , , , . .

9. , . , . , . , , , .

, . .

10. (, , , ) , - . . (, ) .

, Excel, , Excel . . , , , , , , . . . .

11. ( 10), ( 25), 7.1.-2003 , (: [1] [1, 2]).

12. , , , (100150 ) ( , ). .

13. .

14. (..., , , , , , ).

15. . MS Word (*.DOC, *.RTF). ( , _ .doc).

16. . . , - , , , ( ).


17. .

18. , (, , ) .

19. . . , , .

20. .

21. . .

.

:

, . , 23, . , 220114, : (+375-17) 263 64 68;

237 69 : (+375-17) 267 30 : rrpcem@belriem.by belriem@gmail.com,http://www.belriem.by/ .., .., .., .., .., ..

- Ȼ...... ... .., .., ..

- .......................................................................... .., .., .., .., ..

(H1N1) 2009 ................................. .., .., .., .., ..

A/CALIFORNIA/04/2009(H1N1)... .., .., .., .., ..

... .., .., .., .., ..

PNEUMOCYSTIS JIROVECI .................................................................... .., ..

MYCOPLASMA PNEUMONIAE CHLAMYDOPHILA (CHLAMYDIA) PNEUMONIAE ................................................................. ..

.................................................. .., .., .., .., .., ..

2011 ...... .., .., .., .., ..

, 2011 ..................... .., .., .., .., .., .., ..

, .................................................................................... .., .., .., .., .., ..

- - .................................. . ., . .

...................................................................................... .., .., .., .., ..

- .................. .., ..

............................................................................................ .., .., .., .., .., .., .., .., ..

................................................................................................................... .., .., .., .., ..

..................................................................................................... .., .., .., .., ..


..................................................................................................... .., .., .., .., ..

................................................................................................................. .., .., .., .., .., .., ..

- ....................................................................................... ., ., ., M., M.

NEISSERIA MENINGITIDIS .. .., .., ..

. 2011 ........................................................... .., .., .., .., ..

................................................................................. .., .., ..

........................... .., .., .., .., .., .., ..

............................................................. Sprudzns G., Krmia A., Karelis G., Gintere S., Vksna L., Logina I.

SURVEY OF POST-LYME DISEASE SYMPTOMS............................................................................ .., .., ..

........................................................................................... .., .., ..

.......................................................................................... Pheby D.

THE UK NATIONAL ME/CFS OBSERVATORY: THE BALANCE SHEET AFTER THREE YEARS.... .., .., .., .., .., ..

:

................................................................ ..

............................................................................................................. .., .., .., .., .., ..

- ............................................................. , ................................................................. .., .., .., .., ..

.............................................. .., .., .., .., .., .., .., .., ..

................................................................................... .., .., .., ..

.............................................................................................................. .., .., .., .., .., .., ..

.................... .., ., .., .., ..

................................................. .., ..

....................................................................................................... .., .., .., .., .., .., .., ..

.................................. .., .., ..

, ................................................................................................ ., .., .., .., .., ., ..

................................................................ .., .., .., ..

......................................................................................................... .., .., .., .., ..

............................................................................................ .., .., .., .., ..

...................................................................................................... .., .., .., .., ., ..

- .............................................. .., .., .., ..

.............................................................................................. .., .., .., .., .., .., .., ..

................................................................................................ .., .., ..

-............ ..

/ ....................................................... .., .., ..

: .............. .., .., .., .., ..

...................................................................................................... .., ..

, .................................................................... .., .., .., ..

ACINETOBACTER BAUMANNII- :

.................................................................................... .., .., .., .., ..

- , , ....................................................... .., .., .., .., .., ..

1--8- BORRELIA BURGDORFERI...................................................................... .., .., .., ..

PSEUDOMONAS FLUORESCENS, - :

.................................. .., ..

PSEUDOMONAS AERUGINOSA - ............. .., .., .., ..

.......... ..

.................................................................................... ............................................................................................. .., .., .., .., .., .., ..

ϻ............................................................... .., .., .., .., .., .., .., .., .., ..

, /, ........................................................................................................... .., .., ..

/........................................................................................................... Chapenko S., Ziedina I., Folkmane I., Sultanova A., Rozental R., Murovska M.

THE IMPACT OF BETA-HERPESVIRUSES INFECTION ACTIVATION ON EARLY COMPLICATIONS DEVELOPMENT FOLLOWING RENAL TRANSPLANTATION................... .., .., .., ..

- --- .................... Gravelsina S., Nora-Krukle Z., Chapenko S., Sultanova A., Boka V., Cunskis E., Murovska M.

INCIDENCE OF HUMAN HERPESVIRUS 6, 7, AND PARVOVIRUS B19 INFECTION IN PATIENTS WITH THYROID GLAND DISORDERS.................................................................... .., .., .., .., .., .., .., .., .., .., ..

................................................................ ..

........................................................................................ ..

........................................................................................ .................................................................................................................. ............................................................................................................... .. .. , .. , .. .. .. .. 22.12.2011. 6084/8.

. .

. . . 36,27. .-. . 29,32.

115 . 17.

02330/0548510 16.06.2009.

. , 28, 220007, . ./ +375 (17) 216-23- E-mail: med@med.by http://www.med.by

02330/0494258 19.05.2009.

. , 28, 220007, .

Pages:     | 1 |   ...   | 12 | 13 ||
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .